Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18761743 | RECOMBINANT PROTEINS AND THEIR THERAPEUTIC USES | July 2024 | November 2025 | Allow | 16 | 2 | 0 | No | No |
| 18676470 | COMPOSITION FOR INDUCING PROLIFERATION OR ACCUMULATION OF REGULATORY T CELLS | May 2024 | December 2024 | Allow | 7 | 2 | 0 | Yes | No |
| 18636759 | HAEMOPHILUS INFLUENZAE SACCHARIDE-CARRIER CONJUGATE COMPOSITIONS AND USES THEREOF | April 2024 | June 2025 | Allow | 14 | 2 | 0 | No | No |
| 18629715 | NON-PROTEIN CLOSTRIDIAL TOXIN COMPOSITIONS | April 2024 | January 2025 | Allow | 10 | 0 | 1 | No | No |
| 18626126 | MODIFIED BIOTIN-BINDING PROTEIN, FUSION PROTEINS THEREOF AND APPLICATIONS | April 2024 | August 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18437816 | COMBINATION TREPONEMAL AND NON-TREPONEMAL SYPHILIS TEST | February 2024 | April 2025 | Allow | 15 | 1 | 0 | No | No |
| 18430166 | FIBROSIS MODEL AND METHODS OF USE THEREOF | February 2024 | August 2025 | Abandon | 19 | 1 | 1 | No | No |
| 18419900 | MULTIVALENT PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATE COMPOSITION | January 2024 | December 2025 | Allow | 23 | 1 | 1 | Yes | No |
| 18394076 | Foods Providing Probiotic Bacteria | December 2023 | February 2025 | Allow | 14 | 1 | 0 | No | No |
| 18536047 | METHODS AND SYSTEMS FOR DETERMINING PLATELET CONCENTRATION | December 2023 | December 2024 | Allow | 12 | 1 | 0 | No | No |
| 18531055 | Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens and Uses Thereof | December 2023 | December 2025 | Allow | 25 | 1 | 1 | Yes | No |
| 18528697 | METHOD FOR THE TREATMENT OF ALLERGIC RHINITIS | December 2023 | March 2025 | Allow | 16 | 1 | 0 | No | No |
| 18523002 | ENGINEERED BACTERIA SECRETING THERAPEUTIC PROTEINS AND METHODS OF USE THEREOF | November 2023 | September 2024 | Allow | 10 | 1 | 0 | No | No |
| 18516332 | MSP NANOPORES AND USES THEREOF | November 2023 | January 2025 | Allow | 14 | 1 | 1 | No | No |
| 18513577 | METHOD OF IDENTIFYING A BIOLOGICALLY-ACTIVE COMPOSITION FROM A BIOFILM | November 2023 | March 2025 | Allow | 16 | 1 | 1 | No | No |
| 18510385 | MONOVALENT VACCINE FORMULATION AND A METHOD FOR PREPARATION THEREOF | November 2023 | December 2024 | Allow | 14 | 1 | 0 | No | No |
| 18505504 | COMPOSITIONS COMPRISING STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE-PROTEIN CONJUGATES AND METHODS OF USE THEREOF | November 2023 | May 2024 | Allow | 6 | 0 | 0 | No | No |
| 18499938 | ARTICLES COMPRISING A SILK POLYPEPTIDE FOR ANTIGEN DELIVERY | November 2023 | June 2025 | Allow | 19 | 2 | 1 | No | No |
| 18385442 | OBTAINING INFORMATION FROM A BIOLOGICAL SAMPLE IN A FLOW CELL | October 2023 | March 2025 | Allow | 16 | 2 | 0 | Yes | No |
| 18555799 | COMPOSITIONS FOR PRESERVING ANAEROBIC MICROORGANISMS AND METHODS OF MAKING AND USING THE SAME | October 2023 | November 2025 | Allow | 25 | 0 | 0 | No | No |
| 18486166 | RELAY DIRECTIONAL MOLECULAR COMMUNICATION METHOD BASED ON MULTIPLE ATTRACTANTS | October 2023 | November 2025 | Allow | 25 | 0 | 0 | No | No |
| 18485796 | PURIFIED ANTHELMINTIC COMPOSITIONS AND RELATED METHODS | October 2023 | January 2025 | Allow | 15 | 2 | 0 | Yes | No |
| 18376666 | QUIL A FRACTION WITH LOW TOXICITY AND USE THEREOF | October 2023 | August 2024 | Allow | 10 | 1 | 0 | No | No |
| 18474503 | THERAPEUTIC PHARMACEUTICAL COMPOSITIONS | September 2023 | August 2024 | Allow | 11 | 0 | 1 | No | No |
| 18460958 | CHIMERIC IMMUNOGENIC POLYPEPTIDES | September 2023 | October 2025 | Allow | 25 | 1 | 1 | No | No |
| 18365815 | SUBUNIT VACCINE DELIVERY PLATFORM FOR ROBUST HUMORAL AND CELLULAR IMMUNE RESPONSES | August 2023 | October 2025 | Abandon | 26 | 1 | 1 | No | No |
| 18362172 | INHALED RESPIRATORY PROBIOTICS FOR LUNG DISEASES OF INFANCY, CHILDHOOD AND ADULTHOOD | July 2023 | August 2024 | Allow | 13 | 2 | 0 | No | No |
| 18359740 | IMMUNOGENIC COMPOSITIONS, ANTIGEN SCREENING METHODS, AND METHODS OF GENERATING IMMUNE RESPONSES | July 2023 | October 2024 | Allow | 15 | 1 | 0 | No | No |
| 18352801 | MICROBIAL CELLS, METHODS OF PRODUCING THE SAME, AND USES THEREOF | July 2023 | January 2025 | Abandon | 19 | 3 | 0 | No | No |
| 18352362 | PREPARATION OF MAYTANSINOID ANTIBODY CONJUGATES BY A ONE-STEP PROCESS | July 2023 | December 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18271946 | Immunogenic Composition Comprising Multivalent Streptococcus Pneumoniae Polysaccharide-Protein Conjugates | July 2023 | February 2026 | Allow | 31 | 1 | 0 | No | No |
| 18350081 | COMPOSITIONS AND METHODS | July 2023 | December 2025 | Allow | 29 | 3 | 1 | No | No |
| 18341194 | ANIMAL PROTEIN-FREE PHARMACEUTICAL COMPOSITIONS | June 2023 | February 2025 | Abandon | 19 | 0 | 1 | No | No |
| 18258852 | COMPOSITIONS AND METHODS USING AT LEAST ONE STRAIN OF STAPHYLOCOCCUS CARNOSUS THERAPEUTICALLY OR PROPHYLACTICALLY | June 2023 | October 2025 | Allow | 28 | 1 | 0 | Yes | No |
| 18257170 | COMPOSITIONS COMPRISING BACTERIA FOR CANCER IMMUNOTHERAPY | June 2023 | November 2024 | Allow | 17 | 1 | 1 | No | No |
| 18209041 | AAV-MEDIATED DELIVERY OF THERAPEUTIC ANTIBODIES TO THE INNER EAR | June 2023 | November 2024 | Allow | 17 | 1 | 1 | No | No |
| 18330968 | RECOMBINANT LACTIC ACID BACTERIUM AND METHOD THEREOF FOR SIMULTANEOUS TREATMENT AND/OR PREVENTION OF DUST MITE AND COCKROACH ALLERGIES | June 2023 | October 2025 | Allow | 28 | 1 | 0 | No | No |
| 18205718 | SYSTEMS AND METHODS FOR DELIVERY OF A THERAPEUTIC AGENT | June 2023 | December 2025 | Abandon | 30 | 2 | 0 | No | No |
| 18325563 | PERIODONTITIS VACCINE AND RELATED COMPOSITIONS AND METHODS OF USE | May 2023 | June 2024 | Allow | 13 | 1 | 0 | Yes | No |
| 18254555 | AGRICULTURAL COMPOSITION COMPRISED OF THREE SPECIES OF BACILLUS AND MIXED TOCOPHEROLS OF VEGETABLE ORIGIN, WITH POTENTIALIZER EFFECT OF THE BIOFUNGICIDE MECHANISMS AND UV PROTECTION FOR AGRICULTURAL APPLICATION, AND PROCESS OF PRODUCING SAME | May 2023 | October 2025 | Allow | 29 | 1 | 0 | No | No |
| 18197001 | SPORE-CONTAINING PROBIOTIC COMPOSITIONS AND METHODS | May 2023 | February 2024 | Allow | 9 | 0 | 0 | No | No |
| 18252558 | ALL-SCALE SELF-ASSEMBLY AND PRECISE POSITIONING OF SUPRAPARTICLES | May 2023 | August 2025 | Allow | 27 | 0 | 1 | No | No |
| 18315456 | ANTIBODIES TO PfGARP KILL PLASMODIUM FALCIPARUM MALARIA PARASITES AND PROTECT AGAINST INFECTION AND SEVERE DISEASE | May 2023 | March 2024 | Allow | 10 | 0 | 0 | No | No |
| 18310821 | MANNHEIMIA HAEMOLYTICA VECTOR | May 2023 | October 2024 | Allow | 18 | 2 | 0 | Yes | No |
| 18308673 | CULTURE MEDIUM FOR TESTING DRUG RESISTANCE OF H.PYLORI AS WELL AS PREPARATION METHOD AND USE THEREOF | April 2023 | October 2025 | Allow | 30 | 1 | 0 | No | No |
| 18032893 | NOVEL LACTOBACILLUS SP. STRAIN AND USE THEREOF | April 2023 | October 2025 | Allow | 30 | 1 | 0 | Yes | No |
| 18136048 | NON-PROTEIN CLOSTRIDIAL TOXIN COMPOSITIONS | April 2023 | July 2024 | Allow | 15 | 1 | 1 | No | No |
| 18136090 | NON-PROTEIN CLOSTRIDIAL TOXIN COMPOSITIONS | April 2023 | August 2024 | Allow | 16 | 1 | 1 | No | No |
| 18249293 | METHODS FOR THE PREPARATION OF NON-LIVE CHROMOBACTERIUM BIOPESTICIDE | April 2023 | January 2026 | Allow | 33 | 1 | 0 | No | No |
| 18298857 | Separation Matrix | April 2023 | July 2024 | Allow | 15 | 1 | 0 | Yes | No |
| 18126193 | RAPID FERTILITY AND HEALTH INDICATOR | March 2023 | July 2023 | Allow | 4 | 1 | 0 | No | No |
| 18177875 | SYSTEMS AND METHODS FOR DELIVERY OF A THERAPEUTIC AGENT | March 2023 | March 2024 | Allow | 13 | 2 | 0 | No | No |
| 18171969 | LONG LIFETIME ALPHA-HEMOLYSIN NANOPORES | February 2023 | May 2024 | Allow | 14 | 1 | 0 | Yes | No |
| 18166117 | CATH2 DERIVATIVES | February 2023 | August 2024 | Allow | 18 | 1 | 1 | No | No |
| 18014649 | Bacterial Vehicle for Engineering of Non-Phagocytic Immune Cells | January 2023 | December 2025 | Abandon | 35 | 1 | 0 | No | No |
| 18084505 | PROCESS AND SYSTEM FOR OBTAINING BOTULINUM NEUROTOXIN | December 2022 | July 2023 | Allow | 7 | 1 | 0 | No | No |
| 18066582 | Human Streptococcus Pneumoniae Antibodies and Uses Therefor | December 2022 | March 2025 | Allow | 27 | 1 | 1 | No | No |
| 18076133 | CANCER THERAPY | December 2022 | December 2024 | Allow | 24 | 2 | 0 | Yes | No |
| 18057335 | ANTI-BACTERIAL COMPOSITION AGAINST TH1 CELL-INDUCING BACTERIA | November 2022 | April 2024 | Allow | 17 | 1 | 0 | Yes | No |
| 18051844 | METHOD FOR THE TREATMENT OF A RELAPSING-REMITTING CONDITION | November 2022 | February 2025 | Allow | 27 | 0 | 0 | Yes | No |
| 17922779 | COMPOSITIONS COMPRISING BACTERIAL STRAINS AND USE THEREOF FOR THE TREATMENT OF OCULAR DISEASES AND LESIONS | November 2022 | August 2025 | Allow | 33 | 1 | 0 | No | No |
| 18046485 | MODIFIED BIOTIN-BINDING PROTEIN, FUSION PROTEINS THEREOF AND APPLICATIONS | October 2022 | January 2024 | Allow | 15 | 0 | 0 | Yes | No |
| 17962024 | SUSTAINABLY BOOSTING CARBON DIOXIDE FIXATION FOR GROWING MICRO-ALGAE | October 2022 | April 2025 | Allow | 30 | 0 | 0 | No | No |
| 17938188 | STAINING KIT AND METHOD OF IMMUNEPROFILING TO IDENTIFY CHARACTERIZED IMMUNE CELL SUBSETS OF DISEASE AND PREDICTING DISEASE USING THE SAME | October 2022 | October 2025 | Allow | 37 | 1 | 0 | No | No |
| 17937061 | Biologic Machines for the Detection of Biomolecules | September 2022 | February 2025 | Allow | 28 | 2 | 0 | Yes | No |
| 17953789 | PROCESS AND SYSTEM FOR OBTAINING BOTULINUM NEUROTOXIN | September 2022 | February 2023 | Allow | 5 | 2 | 0 | No | No |
| 17953882 | PROCESS AND SYSTEM FOR OBTAINING BOTULINUM NEUROTOXIN | September 2022 | March 2023 | Allow | 5 | 3 | 0 | Yes | Yes |
| 17935139 | DISPLAY SYSTEMS FOR PROTEINS OF INTEREST | September 2022 | August 2024 | Allow | 23 | 1 | 1 | Yes | No |
| 17912681 | FILTRATION UNIT, METHOD FOR PRODUCING SAME, METHOD FOR DETECTING MICROORGANISMS AND USE OF THE FILTRATION UNIT | September 2022 | October 2025 | Allow | 37 | 1 | 1 | Yes | No |
| 17930742 | ISOLATED POLYPEPTIDE OF THE TOXIN A AND TOXIN B PROTEINS OF C. DIFFICILE AND USES THEREOF | September 2022 | February 2025 | Allow | 29 | 2 | 0 | No | No |
| 17929958 | CEACAM BASED ANTIBACTERIAL AGENTS | September 2022 | May 2024 | Allow | 20 | 1 | 0 | No | No |
| 17901315 | ANTIBODY PANEL | September 2022 | September 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17889875 | METHOD FOR THE TREATMENT OR PREVENTION OF INFECTION-RELATED IMMUNE CONDITIONS USING A COMPOSITION COMPRISING IgM | August 2022 | December 2024 | Allow | 28 | 3 | 0 | No | No |
| 17820406 | POLY-N-ACETYL GLUCOSAMINE (PNAG/DPNAG)-BINDING PEPTIDES AND METHODS OF USE THEREOF | August 2022 | July 2024 | Abandon | 23 | 0 | 1 | No | No |
| 17819476 | NEW PROBIOTIC COMPOSITION FOR PREVENTION OF BACTERIAL VAGINOSIS | August 2022 | September 2024 | Allow | 26 | 2 | 0 | No | No |
| 17884675 | Controlling Bacterial Biofilms | August 2022 | August 2024 | Allow | 24 | 1 | 1 | No | No |
| 17798181 | ATTENUATED SALMONELLA SYNTHESIZING ANTIGENS FOR VACCINATING AGAINST HELICOBACTER PYLORI | August 2022 | April 2025 | Allow | 32 | 1 | 0 | Yes | No |
| 17817963 | COMPOSITIONS FOR TREATING VIRAL INFECTIONS AND METHODS FOR SAME | August 2022 | February 2025 | Allow | 31 | 2 | 0 | Yes | No |
| 17879674 | ANIMAL PROTEIN-FREE PHARMACEUTICAL COMPOSITIONS | August 2022 | August 2023 | Abandon | 13 | 2 | 1 | Yes | No |
| 17878834 | MONOVALENT VACCINE FORMULATION AND A METHOD FOR PREPARATION THEREOF | August 2022 | June 2024 | Abandon | 23 | 1 | 0 | No | No |
| 17812777 | IMMUNOGENIC COMPOSITIONS FOR USE IN PNEUMOCOCCAL VACCINES | July 2022 | February 2024 | Allow | 19 | 2 | 0 | Yes | No |
| 17811958 | CHIMERIC NEUROTOXINS | July 2022 | June 2025 | Allow | 35 | 0 | 0 | Yes | No |
| 17845812 | PSGL-1 MODULATORS AND USES THEREOF | June 2022 | December 2024 | Abandon | 30 | 1 | 0 | No | No |
| 17844401 | Compositions And Methods For The Maintenance Of Oral Health | June 2022 | March 2024 | Abandon | 21 | 1 | 0 | No | No |
| 17842635 | RAPID FERTILITY AND HEALTH INDICATOR | June 2022 | September 2023 | Abandon | 15 | 2 | 1 | No | No |
| 17839395 | METHOD OF PRODUCING AN IMMUNOLIGAND/PAYLOAD CONJUGATE | June 2022 | February 2024 | Allow | 20 | 2 | 0 | Yes | No |
| 17837668 | COMPOSITIONS AND METHODS FOR THE SIMULTANEOUS GENOMIC, TRANSCRIPTOMIC AND PROTEOMIC ANALYSIS OF SINGLE CELLS | June 2022 | March 2024 | Allow | 21 | 1 | 0 | No | No |
| 17806242 | DIAGNOSTIC TO DISTINGUISH BACTERIAL INFECTIONS | June 2022 | March 2024 | Abandon | 21 | 1 | 0 | No | No |
| 17835503 | PROCESS AND SYSTEM FOR OBTAINING BOTULINUM NEUROTOXIN | June 2022 | July 2022 | Allow | 1 | 0 | 0 | No | No |
| 17781187 | ANTIBACTERIAL CARBOHYDRATE VACCINE | May 2022 | June 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17781077 | GENETICALLY MODIFIED PHOTOTROPHIC CELL FOR IN-VIVO PRODUCTION OF HYDROGEN | May 2022 | August 2025 | Allow | 38 | 1 | 1 | No | No |
| 17824495 | THERAPEUTIC PHARMACEUTICAL COMPOSITIONS | May 2022 | July 2023 | Allow | 14 | 0 | 0 | No | No |
| 17752707 | CANCER THERAPY | May 2022 | July 2024 | Allow | 26 | 2 | 0 | Yes | No |
| 17779411 | IMMUNOGENIC PROTEIN AGAINST GONOCOCCAL INFECTION | May 2022 | June 2025 | Allow | 36 | 1 | 1 | No | No |
| 17751313 | METHOD FOR THE TREATMENT OF A RELAPSING-REMITTING CONDITION | May 2022 | September 2023 | Allow | 15 | 1 | 0 | Yes | No |
| 17740819 | METHODS OF TREATING PSEUDOMONAS AERUGINOSA RESPIRATORY INFECTIONS | May 2022 | December 2023 | Allow | 19 | 2 | 0 | Yes | No |
| 17737206 | NOVEL BACTERIAL FERMENT OF LACTOBACILLUS SPECIES | May 2022 | April 2024 | Allow | 24 | 1 | 1 | Yes | No |
| 17732951 | PROCESS AND SYSTEM FOR OBTAINING BOTULINUM NEUROTOXIN | April 2022 | February 2023 | Abandon | 10 | 1 | 0 | No | No |
| 17729785 | PURIFIED ANTHELMINTIC COMPOSITIONS AND RELATED METHODS | April 2022 | May 2023 | Allow | 13 | 0 | 0 | No | No |
| 17771103 | METHODS FOR THE DIAGNOSIS OF BURULI ULCER | April 2022 | October 2024 | Allow | 30 | 0 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner NAVARRO, ALBERT MARK.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 23.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner NAVARRO, ALBERT MARK works in Art Unit 1645 and has examined 1,468 patent applications in our dataset. With an allowance rate of 79.8%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 24 months.
Examiner NAVARRO, ALBERT MARK's allowance rate of 79.8% places them in the 49% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by NAVARRO, ALBERT MARK receive 1.38 office actions before reaching final disposition. This places the examiner in the 21% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by NAVARRO, ALBERT MARK is 24 months. This places the examiner in the 81% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +14.0% benefit to allowance rate for applications examined by NAVARRO, ALBERT MARK. This interview benefit is in the 52% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 34.7% of applications are subsequently allowed. This success rate is in the 77% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 50.5% of cases where such amendments are filed. This entry rate is in the 76% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 69% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 90.5% of appeals filed. This is in the 83% percentile among all examiners. Of these withdrawals, 94.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 67.1% are granted (fully or in part). This grant rate is in the 75% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 9.8% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.3% of allowed cases (in the 53% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.